Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the hepatic lowdensity lipoprotein receptor (LDL-R) and is therefore a prominent therapeutic target for reducing LDL-cholesterol. The C-terminal domain of PCSK9 is unlikely to be involved in a direct extracellular interaction with the LDL-R. We probed the importance of the C-terminus for the degradation of the LDL-R by designing seven de novo mutants of PCSK9 that fill potential druggable cavities. The mutants were tested for their ability to diminish LDL uptake in human HepG2 cells and for affinity towards a calcium independent mutant of the EGF(A) domain of the human LDL-R. The later was done by a newly developed surface plasmon resonance-based assay format. We identified three mutant proteins (G517R, V610R and V644R) with decreased ability to block LDL uptake into HepG2 cells. These mutations define areas outside the direct interaction area between PCSK9 and the LDL-R that could be targeted to inhibit the PCSK9 triggered degradation of the LDL-R. We also describe the mechanistic rationalisation of the affinity changes seen with the natural occurring human D374Y (gain of function) mutation causing severe hypercholesterolaemia. The action of this mutant is due to a significantly decreased dissociation rate constant, whereas the mutation does not affect the association rate constant.
Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the ninth member of the family of mammalian subtilisin-like serine proprotein convertases, first discovered by Seidah et al. (2003) . The description of mutations in PCSK9 revealed the important link between PCSK9, hypercholesterolaemia and premature coronary heart disease (Abifadel et al., 2003; Leren, 2004; Cohen et al., 2006) and demonstrated that PCSK9 expression is regulated by cholesterol (Horton et al., 2003; Maxwell et al., 2003) . PCSK9 promotes the degradation of the hepatic low-density lipoprotein receptor (LDL-R) (Maxwell and Breslow, 2004; Horton et al., 2007) , a key player in regulating plasma cholesterol levels (Goldstein and Brown, 2009) . Consequently, loss of function mutations leads to higher levels of the LDL-R, as PCSK9 functions through a posttranslational regulation of the number of LDL-R molecules through binding to the EGF(A) domain of the receptor and initiating the intracellular degradation of the LDL-R (Kwon et al., 2008; Seidah and Prat, 2012) . Those findings make PCSK9 an attractive target for pharmaceutical intervention to treat hypercholesterolaemia and associated cardiovascular disease (Marais et al., 2012; Seidah, 2013) . Indeed, several recent phase-II clinical trials using monoclonal antibodies directed towards PCSK9 have been conducted and have shown a >60% reduction of LDL-cholesterol and phase-III clinical trials have been initiated (McKenney et al., 2012; Desai et al., 2013) . However, to the best of our knowledge there are very limited reports of small molecule inhibitors interacting directly with PCSK9 and inhibiting the PCSK9-induced degradation of the LDL-R (Pingali et al., 2011 (Pingali et al., , 2012 .
PCSK9 is a 692 amino acid multidomain protein that contains a prodomain, a catalytic domain, a hinge-region and a cysteine-histidine rich C-terminal domain (Saavedra et al., 2012) . Several crystal structures of PCSK9 alone or in combination with either parts of, or the full, extracellular section of the LDL-R have been published (Cunningham et al., 2007; Hampton et al., 2007; Piper et al., 2007; Kwon et al., 2008; Lo Surdo et al., 2011) . The co-structure of PCSK9 and LDL-R at neutral pH reveals that the PCSK9 C-terminal domain is exposed to solvent, enabling possible cofactor binding. In contrast, the catalytic domain and prodomain interact with the LDL-R EGF(A) and β-propeller domains, respectively (Lo Surdo et al., 2011) . Although numerous hydrogen bonds and salt-bridges are formed between PCSK9 and the EGF(A) domain, the proteinprotein interaction (PPI) surfaces are primarily hydrophobic and large (Kwon et al., 2008) . Furthermore, the EGF(A) binding surface on PCSK9 is quite flat, displaying no deep cavities for small molecules to bind. Hence, discovering small molecule inhibitors binding to these interaction surfaces and breaking the PPI between the EGF(A) domain of the LDL-R and PCSK9 appears challenging and most likely explains the lack of reported small molecule PPI inhibitors.
On the other hand, the C-terminal domain of PCSK9 has also been shown to be important for the process of the intracellular degradation of the LDL-R. Holla et al. (2011b) showed that the net charges of the C-terminal domain play a role in the degradation of the LDL-R and they demonstrated that the positively charged C-terminal domain increases the binding of PCSK9 to the LDL-R. Furthermore, this group (Tveten et al., 2012) revealed that the C-terminal domain is necessary to allow PCSK9 to remain bound to the LDL-R in the endosomeacidified state. Saavedra et al. (2012) further demonstrated that residues 530-605 of the C-terminal domain are needed for the interaction of PCSK9 with the LDL-R. These studies support the finding reported by Ni et al. (2010) , that a Fab fragment (1G08) binds a region of PCSK9 in its C-terminus from residues 549 to 612 and thereby inhibits the internalisation of the PCSK9 LDL-R complex, thus increasing LDL uptake. A recently reported structure with another Fab fragment from the different antibody mAb1 shows an alternative interaction pattern by engaging specifically with residues 469, 496 and 515 (Schiele et al., 2014) . The antibody mAb1 was able to demonstrate a partial reduction of LDL-C levels in vivo in nonhuman primates. Finally, the C-terminal domain of PCSK9 has been reported to bind to annexin A2 which acts as an extrahepatic inhibitor of PCSK9-induced LDL-R degradation (Mayer et al., 2008; .
The aim of this study was to investigate the importance of potential druggable cavities on the protein surface of the C-terminal domain of PCSK9 as well as to further characterise the importance of the C-terminus of PCSK9 for the degradation of the LDL-R through a mutation analysis. Instead of using a large and diverse set of amino acid residues, the number of point mutations was reduced to an experimentally acceptable level by selecting only positively charged amino acids as one extreme (with an exception where an arginine was replaced). This fitted well with our ambition to find specific mutations that would negatively impair the binding of PCSK9 to LDL-R that are not driven by charge repulsion, as it is known that positively charged amino acid residues typically lead to an increase in the affinity of PCSK9 to the LDL-R (Holla et al., 2011b) . Therefore, seven point mutants in the C-terminal domain of PCSK9 were designed based on the publicly available crystal structures and characterised in a functional cell assay for LDL uptake into HepG2 cells.
We also tested if these mutations in the C-terminus might influence the direct interaction with the EGF(A) domain of the LDL-R. Here we describe three artificial loss of function mutations G517R, V610R and V644R in the C-terminal domain of PCSK9 that define areas outside the direct interaction area between PCSK9 and the EGF(A) domain of the LDL-R that can potentially be targeted with small molecules to inhibit the PCSK9 triggered degradation of the LDL-R.
Results

PCSK9 mutants
The 692 amino acid human PCSK9 contains a signal peptide and a prodomain followed by a catalytic protease domain, a hinge-region and a C-terminal domain. The X-ray crystal structure of PCSK9 in complex with the EGF(A) domain of the LDL-R or full extracellular domain of the LDL-R has been published (Kwon et al., 2008; and shows that the C-terminal domain of PCSK9 is unlikely to be involved in a direct interaction with the LDL-R. Analysis of the publically available X-ray crystal structures of the C-terminal domain (Hampton et al., 2007) reveals cavities that appear amenable to serve as potential binding pockets for small molecules. Hence, we de novo designed seven point mutants that fill these cavities in the C-terminal domain: G517R, E569K, V610R, S636R, V644R, R659A and R659E. We also included in our study two naturally occurring mutations in the C-terminal domain: R469W and F515L (Allard et al., 2005; Kotowski et al., 2006) , as well as one in the PCSK9 prodomain reported to have a higher affinity towards LDL-R than wild-type (wt) PCSK9: S127R (Cunningham et al., 2007) . In addition, to compare the impact of these mutations with direct changes in the PPI between PCSK9 and the EGF(A) domain of the LDL-R we designed two de novo mutants which we assumed to impair the PCSK9 LDL-R interaction: S372W and S372H. Finally, the well-characterised gain of function mutation D374Y in the PCSK9 LDL-R interaction area (Cunningham et al., 2007) that significantly increases the affinity between PCSK9 and LDL-R was included. The locations of the discussed mutations in PCSK9 are indicated in Fig. 1 .
Screening for effect of the mutants
All mutants were expressed as recombinant proteins using the baculovirus expression vector system (BEVS). To narrow down the number of mutants to characterise in detail, they were subjected to one round of screening. Supernatants from 20 ml cultures infected with a multiplicity of infection = 1 for each virus containing either wt PCSK9, the different mutants or an empty MOCK control virus were used in the BODIPY-LDL uptake assay in HepG2 cells. The concentration of wt PCSK9 or each mutant PCSK9 variant in the supernatants was determined by ELISA methodology (Lambert et al., 2008) . The difference in BODIPY-LDL uptake with wt PCSK9 compared with MOCK insect cell culture supernatant was arbitrarily set to 1. A value >1
indicates a gain of function mutant, as this mutant inhibits the uptake of BODIPY-LDL to a greater degree than wt PCSK9. On the other hand, a value <1 indicates a loss of function mutant, because this PCSK9 mutant allows the cells to take up more BODIPY-LDL than wt PCSK9. All results were corrected for the concentrations of wt PCSK9 or mutants as determined by ELISA. The results are summarised in Table I . From the two mutations at the interaction site between LDL-R and PCSK9 (S372W and S372H), PCSK9(S372W) showed a 67% loss of function compared with wt PCSK9. Three mutations in the C-terminal domain showed an even greater loss of function, with the PCSK9(V644R) mutant displaying 90% loss of function. These three PCSK9 mutants PCSK9(G517R), (V610R) and (V644R) were therefore chosen for purification and further characterisation.
Characterisation of selected mutants from the screening
All mutants and wt PCSK9 were expressed using the BEVS and purified as described in 'Materials and methods' section using their C-terminal His-tags and Ni-NTA resin.
The three selected de novo mutants were subsequently assessed and compared in dose response experiments with wt PCSK9 and the gain of function mutant PCSK9(D374Y) in the cellular assay of BODIPY-LDL uptake into HepG2 cells. The results are summarised in Table II . For the calculation of the IC 50 , the effect of PCSK9 (D374Y) at 15 µg/ml was set as the full inhibition control. As expected PCSK9(D374Y) blocked LDL uptake very efficiently, even at the lowest concentration tested (0.5 µg/ml). The three prioritised C-terminal domain mutants showed a reduced ability to block LDL uptake when compared with wt PCSK9. PCSK9(V610R) displayed the most pronounced loss, followed by PCSK9(G517R) and PCSK9(V644R).
To initially characterise the interaction of the mutants towards the LDL-R, a previously developed surface plasmon resonance (SPR) in solution binding assay was selected (Bottomley et al., 2009; Liu et al., 2010; . In this assay, soluble LDL-R was tethered to the sensor, and wt and mutant PCSK9 proteins were used as the analyte ( Fig. 2A) . By appreciating the complex binding mechanism as evident from SPR sensorgrams from the other research groups (Bottomley et al., 2009; Liu et al., 2010; as well as our own data (not shown), we performed a steady-state analysis of the SPR data instead of applying a kinetic analysis following a simple 1:1 binding model. As evident from Table III and in agreement with other data presented in this study, the C-terminal mutated PCSK9 variants showed no significant difference in their binding to soluble LDL-R when compared with wt PCSK9, even though all displayed a slightly lower affinity. In line with expectations based on literature data (Cunningham et al., 2007; Pandit et al., 2008) , the variant PCSK9(D374Y) with the mutation at the PCSK9-LDL-R interaction interface bound more tightly compared with wt PCSK9.
To address these previously outlined steady-state assay limitations and to have an additional dataset to support our hypothesis, we developed a novel direct binding assay that makes use of the EGF66 peptide 1.7 ± 0.14 0.009 1.4
A gain of function mutant will show a lower IC 50 value because it inhibits the uptake of BODIPY-LDL at lower concentrations compared with wt PCSK9. On the other hand, a loss of function mutation will show an increased IC 50 compared with wt PCSK9, as it does not block BODIPY-LDL uptake into HepG2 cells as efficiently as wt PCSK9. IC 50 values are presented as an average ± standard deviation from three measurements. The significance of the difference in IC 50 was tested by unpaired t-test and the P values are given. The increase in IC 50 for the de novo mutants in comparison with wt PCSK9 is also indicated as fold-change. Inhibition of BODIPY-LDL uptake by wt PCSK9 and PCSK9 mutants. The difference in BODIPY-LDL uptake with wt PCSK9 compared with MOCK insect cell culture supernatant (full and uninhibited BODIPY-LDL uptake) was set to 1. A value >1 indicates a gain of function mutant, as this mutant inhibits the uptake of BODIPY-LDL to a greater degree than wt PCSK9 (the difference to MOCK becomes greater). On the other hand, a value <1 indicates a loss of function mutant, because this PCSK9 mutant allows the cells to take up more BODIPY-LDL than wt PCSK9 and the difference compared with MOCK becomes smaller. All results were corrected for the concentration of wt PCSK9 or mutants as determined by ELISA. Results are from one round of screening. as analyte to interrogate biosensor-tethered PCSK9 (Fig. 2B) . The EGF66 peptide (Zhang et al., 2012 ) is a calcium independent variant of the EGF(A) domain of the LDL-R that interacts with the catalytic domain of PCSK9. This assay configuration allowed for a more effective comparison between different protein preparations/constructs in terms of ligand binding competence as well as affinity, which is also highlighted by the significantly smaller errors observed in those measurements. Furthermore it provided us with better opportunities to control and determine the active concentration of the analyte. In line with the data from the SPR in solution binding assay, the results produced by this assay configuration could further strengthen our hypothesis, as we could observe an almost unchanged affinity of the C-terminal mutated PCSK9 variants when compared with wt PCSK9 (Fig. 2C and Table IV ). The gain of function mutant PCSK9(D374Y) bound the EGF66 peptide more tightly compared with wt PCSK9.
In summary, our results suggest that the G517R, V610R and V644R loss of function mutations in PCSK9 define areas outside the direct interaction area between PCSK9 and the LDL-R that decrease the effect of blocking LDL uptake without effecting the interaction with the EGF(A) domain of the LDL-R.
Discussion
The results described herein show that the structure of the C-terminus of PCSK9 plays an important role in the degradation of the LDL-R independent of the affinity towards the EGF(A) domain as shown by the amount of BODIPY-LDL uptake into HepG2 cells. Ni et al. showed that an antigen-binding fragment binding at the C-terminal domain of PCSK9 inhibited PCSK9 internalisation and restored LDL uptake (Ni et al., 2010) . Furthermore, they showed that this antigen-binding fragment 1G08 binds a region of β-strands encompassing R549, R580, R582, E607, K609 and E612 in the PCSK9 C-terminal domain and that it does not interfere with the binding towards the LDL-R. Interestingly, the mutation V610R, which showed the most pronounced loss of effect of the C-terminal mutations tested in the cellular LDL uptake assay, is located in the region that is described to be covered by 1G08. In contrast to our observations with the V610R mutant, the removal of charged residues in that β-strand region as seen with the triple mutant E607A:K609A:E612A did not show any significant differences in LDL uptake (Ni et al., 2010) . The introduction of a charged residue rather the removal of several charges in that β-strand region can obviously lead to different physiological consequences, which will require further investigations to rationalise this. Recently, Schiele et al. demonstrated that this antibody (mAb1) directed towards a different region of the C-terminal domain of PCSK9 was able to partially reduce LDL-C levels in nonhuman primates (Schiele et al., 2014) . The antibody mAb1 acts by primarily interacting with R469, R496 and F515, and thus, in a region that has been shown to be important for LDL-R degradation by genetic findings. The G517R mutant described in this study is within this binding epitope, highlighting the possibility that small molecule binders exploring this region can modulate PCSK9 function.
In addition to the already published work on the function of the C-terminal domain of PCSK9 (Mayer et al., 2008; Ni et al., 2010; Holla et al., 2011a; Saavedra et al., 2012; Tveten et al., 2012) , the de novo mutations created in this investigation highlight regions of PCSK9 with potential interest for small molecule drug discovery. The introduced mutations do not perturb the PPI but still inhibit the effect of PCSK9 in reducing LDL uptake, and hence, the mutation can potentially mimick the effect of a small molecule located at the same location. PPIs play a central role in many biological processes and constitute one of the most interesting classes of molecular targets that could lead to a wide variety of novel and valuable therapeutics (Arkin and Wells, 2004) . Whilst there have been successful examples of the discovery of small molecule inhibitors of PPIs, these have been relatively few and the search for modulators of PPIs has proven incredibly challenging (Fry, 2012) . This is likely due to a combination of the extended surface area of the protein-protein interface and the often flat nature of the protein interaction surface, devoid of defined pockets often associated with the binding of a small molecule to a protein. As a result, common hit finding strategies, such as high throughput screening of large compound libraries have proved less successful with PPIs, mainly due to the suboptimal tailoring of the compound collections but also due to the inherent topological and physicochemical specificities associated with the protein interfaces themselves. Not all PPIs have equivalent druggability (Hajduk et al., 2005; Chen et al., 2011) . Hence, a range of novel hit finding and screening approaches are being developed to allow the modulation of previously inaccessible PPI targets (Ofran and Rost, 2007; Bower and Pannifer, 2012; Desimmie et al., 2012) . In this context, our presented approach focused on the identification of possible interaction sites for small molecules that then could be exposed to a greater diversity of tools to discover novel modulators of this PPI.
The EGF(A) binding surface on PCSK9 buries around 500 Å 2 of otherwise solvent accessible surface, and is located ∼20 Å away from the active site, i.e. partially occupied by the cleaved N-terminal PCSK9 variant The kinetic rate constants k on and k off and the dissociation rate constant K D were extracted by kinetic analysis of the SPR sensorgrams by applying a simple 1:1 binding model. The data represent the average of three independent measurements with the standard deviation given as errors. The parameter R max describes the normalised maximal analyte responses under steady-state conditions and reflects the surface activity and ligand binding competence. The dissociation rate constant K D was extracted through steady-state analysis of the SPR sensorgrams by applying a simple 1:1 binding model. The data represent the average of three independent measurements with the standard deviation given as errors. The parameter R max describes the calculated maximal analyte responses for the different protein preparations assuming full saturation of binding.
domain. The only side chain showing a significant conformational change upon binding of EGF(A) is R194 (Kwon et al., 2008) . Although the EGF(A) binding surface on PCSK9 shows numerous possibilities for directional interactions such as hydrogen bonds and salt-bridges, the productive exploitation of these seems, due to the lack of buried cavities, to be limited to larger molecules such as proteins, peptides and possibly macrocycles.
We investigated the EGF(A) PCSK9 interaction interface for suitable cavities to place anchor fragments, which have the potential to be expanded until the resulting compounds have the opportunity to interfere with EGF(A) binding. One such area presents itself around S372 with a possible expansion via D374 towards the PPI surface, and a second direction for expansion into the partially occluded active site cleft. Indeed, the S372 mutations, screened by us in this work, show a pronounced loss for function in the cell assay for LDL uptake ( Table I) .
The two SPR assay configurations furnished the opportunity to compare the different mutants in their ability to bind the soluble LDL-R and the EGF66 peptide. As apparent from Tables III and IV, there are no significant differences in the binding affinities of either the soluble LDL-R or the EGF66 peptide binding to wt PCSK9, and the three PCSK9 mutants (G517R, V610R and V644R) that are altered in their C-terminal domain. Taking into account both the affinity and the kinetic signatures of EGF66 binding, the PCSK9 variants appear to be indistinguishable from one another, suggesting that the mutations do not impact on the direct interaction of LDL-R with PCSK9. The differences seen in the R max values are a reflection of differences in the ligand binding competence of the different protein preparations as well as the changes in protein immobilisation and orientation on the biosensor, which has some consequences for the SPR in solution binding assay. By applying the concept of a direct binding assay using a well-characterised analyte, we could achieve an accurate and quantitative comparison of the different mutations and their impact on LDL-R binding using EGF66 as a surrogate. Despite the different assay configurations, the results for the three C-terminal PCSK9 mutants (G517R, V610R and V644R) indicate an unchanged binding behaviour when compared with wt PCSK9 in both assay configurations, thus providing a solid foundation to build an hypothesis around the function of the C-terminal region of PCSK9. The significant differences in the affinities between the in solution assay using the ectodomain of the LDL-R and the direct binding assay applying the EGF66 peptide as analyte as seen in Tables III and IV is a consequence of the more complex and different interaction mode with the LDL-R, which is not following a simple 1:1 binding process as for example seen with the EGF66 peptide (Fig. 2C ). The data with the LDL-R have thus been subjected to a steady-state analysis to arrive at a macroscopic affinity value, with the caveat that potential unspecific binding effects will impact on the affinity values to a greater extend.
The additional information provided by the direct binding SPR assay in terms of resolving the measured affinity into binding rate constants enables a mechanistic rationalisation of the affinity changes seen with the D374Y (gain of function) mutant. As apparent from the data in Table IV , the affinity is altered mainly due to a significant decrease in the dissociation rate constant (k off ) by ∼20-fold, which manifests directly in an affinity gain within a similar order of magnitude, as the association rate constant (k on ) is basically unaffected. The decreased dissociation rate reflects an increase in the free energy of activation for the dissociation, which can be attributed to an additional hydrogen-bond formation of the tyrosine residue with H306 in the EGF-A domain of LDL-R, which is also present in the EGF66 peptide sequence. Another interesting aspect of the direct binding assay is the possibility, to use this either as a primary screening tool to find small molecule fragments that show direct engagement with PCSK9 or as a secondary screening tool to validate and characterise hits that come for example from a biochemical or cellular screen directed towards this challenging PPI.
Another area of interest is the C-terminal domain of PCSK9. By mimicking the potential effect of a small molecule by introducing a mutation in the protein, we found three novel loss of function mutations of PCSK9: G517R, V610R and V644R. However, it should be noted that they were selected on the basis of one screening round, leaving a chance of variation and of course of missing a false negative mutant. The effects seen in this screening round may also be influenced by the insect cell culture medium added to the BODIPY-LDL uptake assay at this stage. A 25% (v/v) insect cell culture medium was used in the assay. This medium has pH of 6.2 and also contains a number of proprietary complex supplements by the producer (e.g. yeastolate), both factors that make this screening assay considerably different from the later characterisation of the selected mutants under well described and controlled conditions. With respect to the positive charge of the mutants G517R, V610R and V644R, the lower pH caused by the insect cell medium is a likely cause of the different effects seen between the initial screening and the final detailed characterisation (Tables I  and II) .
The PCSK9 protein surface around G517 is very shallow, i.e. no pronounced pocket to support small molecule binding. However, the mutation to a larger arginine group may disrupt putative interactions with other proteins. The mutation V644R is located at the end of a loop of variable conformation, giving rise to a pocket of variable shape in the unbound state, as seen in available PCSK9 X-ray structures (PDB http://www.rcsb.org/, PDB IDs: 2P4E, 2PMW, 3BPS, 3GCW, 3GCX, 3H42, 3M0C, 3P5B, 3P5C, 3SQO) that is in need of further structural characterisation with bound small molecule ligands. The mutation V644 packs tightly against A637, and consequently a mutation to arginine will disrupt the structure of the C-terminal domain's M3 module . A rare natural V644I mutation in human PCSK9 was found not to affect LDL-cholesterol levels in a Japanese population (Miyake et al., 2008) . From a structure-based design perspective, the surface around V610, which is located within a β-strand, is of particular interest. This residue is part of a cleft between the M2 and M3 modules of the C-terminal domain (Cunningham et al., 2007) . From residue V610, a bound small molecule ligand could be expanded in several directions along this cleft, e.g. towards L606, or in the direction of E612. A mutation V610R is hypothesised to affect both the packing of C-terminal modules M2 and M3 against one another, as well as to possibly interfere with any protein binding to the M2-M3 interface. This is also the mutation in the C-terminal domain that showed the most pronounced loss of function in the LDL uptake assay (Table II) . It should be noted that this structure is missing a β-strand in the M2 module (Cunningham et al., 2007) , whilst further structural studies show this strand with the R582 sidechain approaching residue V610, thus revealing potential limitations with the outlined strategy (Lo Surdo et al., 2011) . However, the likely plasticity of this region as evidenced by the inability to define and resolve this region in most of the reported crystal structures, would likely leave room to accommodate the V610R mutation and more importantly, could still provide an opportunity for successful small molecule design targeting that region.
In summary, PCSK9 is a challenging but highly validated PPI target that has, to date, proven to be refractory using traditional lead generation approaches. No small molecules are reported and validated that could effectively modulate the interaction with the LDL-R receptor. Finding molecules with such properties would be highly rewarding despite the existing antibodies and RNA approaches that are currently progressing through clinical trials. Even though antibodies that are directed against the C-terminal region show only partial inhibition and can be rather regarded as modulators, small molecules targeting that region can still be of high value even if they experience a similar mode of action. First, the oral availability can be greatly enhanced thus helping patient compliance. Secondly, a discrete modulation of the PCSK9-LDL-R interaction may address some potential risks relating to insufficient liver regeneration and elevated probability for hepatitis C infections (Zaid et al., 2008; Labonte et al., 2009) . Our results described herein, in particular the surface around V610R, point towards potential regions outside the direct EGF(A) domain-PCSK9 interface with enticing binding pockets that can potentially be targeted by small molecules. The newly described direct binding assay provides an excellent opportunity for application in small molecule hit finding campaigns either as a primary (e.g. fragment screening) or as a secondary (e.g. hit validation) screening assay. In that respect, the described PCSK9 mutants can also play an important role during the characterisation of small molecule modulators of PCSK9 function. Taken together, these findings provide new opportunities in the search for new therapeutic options in this exciting area to treat cardiovascular disease.
Materials and methods
Design of PCSK9 mutants
The PCSK9 protein surface was analysed using SiteMap (Schrödinger, LLC, New York, NY) (Halgren, 2007) in order to characterise the hydrophobic and polar interactions. Fred_receptor (OpenEye Scientific Software, Santa Fe, NM) was used to visualise the corresponding docking cavity. Site-directed mutations were designed by replacing the original side chain of an amino acid by the desired mutant side chain. The orientation of the mutant side chain was optimised by a conformational search using rotamer libraries and energy minimisation (MAESTRO/PRIME (Schrödinger, LLC) (Jacobson et al., 2002) keeping the surrounding residues restrained.
Expression of wt PCSK9 and mutants
All expression constructs were delivered by Geneart in the vector pVL1393 (BamHI/NotI). All constructs had a C-terminal extension with a 8xHis tag: PGDDDDKHHHHHHHHSGS.
Virus for expression in the BEVS was created using BD BaculoGold Bright Baculovirus DNA (BD Bioscience) according to the manufacturer's instructions.
Shaker cultures with Sf9 (2 × 10 6 cells/ml) in SFII900 with L-glutamine medium (Invitrogen) were infected with a multiplicity of infection = 1. The infected cells were incubated for 4 days at 27°C , 100 rpm. After incubation, the supernatant was separated from the cells by centrifugation at 6000 × g for 45 min and stored at-80°C until use. The virus titre was determined using titration of virus by endpoint dilution as described in King and Possee (1992) . The concentration of wt PCSK9 or mutants in the cell culture supernatants was determined by ELISA as described by Lambert et al. (2008) .
Purification of wt PCSK9 and mutants
Cell culture supernatant was concentrated using Quattro flow (Omega screen medium 30 kDa PALL) and a buffer exchange into 50 mM Tris-HCl pH 8, 1 M NaCl (buffer A) was performed at the same time. Ni-NTA Superflow (Qiagen) was equilibrated in buffer A and the buffer exchanged cell culture supernatant was loaded onto it. The His-tagged wt PCSK9 and the mutants were eluted using a gradient from 0 to 300 mM imidazole in buffer A. Fractions were analysed by SDS-PAGE and pooled accordingly. Before storage at -80°C, imidazole was removed by performing a buffer exchange using PD10 columns (GE Healthcare) with buffer A.
Human BODIPY-LDL uptake in HepG2 cells
Cryo-preserved HepG2 cells were thawed quickly at 37°C and mixed with pre-warmed culture medium (MEM) (with Glutamax-1, Earle's salts and Hepes) (Gibco), 1 mM NaPyruvate (Gibco), 1 × NEAA (Gibco), 1 × Pest (Gibco), centrifuged at 200 × g for 5 min at room temperature and resuspended with culture medium with the addition of 5 mg/ml lipoprotein deficient serum (LPDS) (Intracel). Cells were then seeded at 100 000 cells/cm 2 in 50 µl/well in Biocoat, Poly-D-Lysine 96-well plates (Becton Dickinson) and incubated for 24 h at 37°C and 5% CO 2 .
Additions, e.g. purified PCSK9, were then prepared at 4-fold the required final concentration in culture medium with the addition of 5 mg/ml LPDS and 25 µl were added per well, and the plates were incubated for another 1 h. Alternatively, 25 µl/well of insect cell culture supernatant from expression cultures was added. Finally, 25 µl/well of 10 µg/ml BODIPY-LDL (Invitrogen) in culture medium with 5 mg/ml LPDS was added and the plates incubated for another 4 h.
The cells were then fixated by addition of 10 μl/well 37% formaldehyde. After incubation at room temperature for 10-20 min, the cells were washed three times with 100 µl phosphate-buffered saline (PBS) and the nuclei were stained by adding 50 µl Hoechst at 1 µg/ml (Invitrogen) diluted in PBS. After incubation at room temperature for 30 min, the cells were washed three times with 100 µl PBS and 100 µl PBS added per well. Subsequently, the uptake of BODIPY-LDL into the cells was quantified by image analysis using Arrayscan VTI and the software Compartmental Bioapplication (Thermo Scientific Cellomics). The modality CircSpotAvgInt was used to specifically quantify the BODIPY staining generated in the intracellular lipid droplet compartments.
Calculations
IC 50 calculations and unpaired t-test were carried out using SigmaPlot 8 (Systat Software Inc.). If purified wt PCSK9 or PCSK9 mutant was used in the experiments, the protein concentrations used for calculations were corrected to reflect the amount of wt PCSK9 or PCSK9 mutant and not total protein using the imaging QuantityOne software (Biorad) and Comassie stained SDS-PAGEs of the purified fractions.
SPR experiments with EGF66 peptide EGF66 peptide (Zhang et al., 2012) was purchased from Bachem.
SPR experimental conditions
The SPR experiments were all performed on a Biacore T200 optical biosensor unit (GE Healthcare). Sensor chips Series S CM5 (Research grade) were obtained from GE Healthcare. Prior to use, all sensor chips were left at room temperature for 15 min to prevent water condensation on the detector side of the sensor chip surface. The running buffer was made from HBS-P(+), 10× (BR-1006-71 from GE Healthcare) diluted to 10 mM HEPES, 150 mM NaCl, 0.05% Tween 20 and supplemented with 2% DMSO. All binding experiments with the EGF66 peptide were performed at 25°C using a flow rate of 30 µl/ min. The contact time for the conventional multi-cycle kinetic studies was 1 min followed by a 10 min dissociation phase. No regeneration was required. For single-cycle kinetics, a contact time of 2 min was selected, followed by a 1 h dissociation phase to allow for a proper estimation of the dissociation rate constant. The EGF66 peptide was dissolved in 100% DMSO to a stock concentration of 10 mM. A dilution into running buffer devoid of DMSO was made to match the DMSO content of the running buffer, yielding a concentration of 200 µM. This was further diluted in running buffer to yield a starting concentration of 10 µM for the analysis. For the nine-point concentration response applying multi-cycle kinetic studies, this was further diluted in 3-fold steps in running buffer with the lowest analyte concentration of 1 nM. For the single-cycle kinetics, the following five concentrations have been selected to conduct the series of five injections: 1000, 100, 30, 10 and 3 nM. For the analysis, three running buffer blanks were injected to equilibrate the instrument. The data collection rate was set to 10 Hz and all experiments have been repeated three times to allow for error estimations.
Tethering of wt PCSK9 and mutants for SPR
For the tethering of wt PCSK9 and mutants onto a CM5 biosensor chip, a coupling buffer containing 10 mM 2-(N-morpholino)ethanesulfonic acid pH 6.4 was used. The surface was activated for 10 min with 0.05 M NHS and 0.2 M EDC, followed by an injection of the respective protein variant in coupling buffer at a concentration of 30-60 µg/ml with a contact time of 1-2 min to achieve the desired densities of 3000-3800 RU. This was followed by deactivation of residual esters with 0.5 M ethanolamine hydrochloride, pH 8.5 for 6 min. The tethering was performed at 25°C and at a flow rate of 10 µl/min. Reference surfaces were prepared accordingly, omitting the injection of protein over the activated reference surface.
SPR experiments with LDL-R ectodomain
Soluble LDL-R (ectodomain) was purchased from R&D Systems.
SPR experimental conditions
The SPR experiments were all performed on a Biacore T200 optical biosensor unit (GE Healthcare). Sensor chips Series S CM5 (Research grade) were obtained from GE Healthcare. Prior to use, all sensor chips were left at room temperature for 15 min to prevent water condensation on the detector side of the sensor chip surface. The running buffer was made from HBS-P(+), 10× (BR-1006-71 from GE Healthcare) diluted to 10 mM HEPES, 150 mM NaCl, 0.05% Tween 20 and supplemented with 0.5 mM CaCl 2 . All binding experiments were performed at 25°C using a flow rate of 20 µl/min. The contact time for the different PCSK9 preparations was 2 min followed by a 3 min dissociation phase. Regeneration of the biosensor was achieved by injecting a 1:1 mixture of 50 mM NaOH and 50 mM Glycine pH 9.50. For the 10-point concentration response studies, wt and mutant PCSK9 proteins were injected at a concentration range of 500-1 nM using a 2-fold dilution pattern. For the analysis, three running buffer blanks were injected to equilibrate the instrument. The data collection rate was set to 10 Hz and all experiments have been repeated three times to allow for error estimations.
Tethering of LDL-R ectodomain for SPR
For the tethering of soluble LDL-R (residues 22-788; 10 μg/ml in 10 mM sodium acetate, pH 5.0; R&D Systems) onto a CM5 biosensor, the surface was activated for 5 min with 0.05 M NHS and 0.2 M EDC, followed by an injection of the soluble LDL-R with a contact time of 30-45 s to achieve the desired low densities of 100-150 RU. This was followed by deactivation of residual esters with 0.5 M ethanolamine hydrochloride, pH 8.5 for 5 min. The tethering was performed at 25°C and at a flow rate of 10 µl/min. Reference surfaces were prepared accordingly, omitting the injection of protein over the activated reference surface.
